Actively Recruiting
EVT in Acute Basilar Artery Occlusion With Large Infarction Core
Led by The First Affiliated Hospital of Hainan Medical University · Updated on 2025-07-29
348
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A multicenter, prospective, open-label, blinded endpoint, randomized controlled trial designed to evaluate the efficacy and safety of best medical management (BMM) combined with endovascular treatment (EVT) versus BMM alone in acute basilar artery occlusion (BAO) patients with large infarct cores.
CONDITIONS
Official Title
EVT in Acute Basilar Artery Occlusion With Large Infarction Core
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Symptoms and signs consistent with basilar artery ischemia
- Basilar artery or vertebral artery occlusion confirmed by CTA, MRA, or DSA; complete obstruction of blood flow to the basilar artery if vertebral artery occlusion is present
- POST-NIHSS score 10 or higher at randomization
- Time from symptom onset to randomization within 24 hours
- pc-ASPECTS score of 3-5 on CT/MRI for patients under 80 years old or 3-7 for patients 80 years or older
- Willingness to comply with protocol requirements and provide informed consent
You will not qualify if you...
- Pre-stroke modified Rankin Scale (mRS) score greater than 2
- Factors in the target vessel that may prevent completion of endovascular treatment
- Concurrent anterior and posterior circulation strokes or multivessel occlusions
- Significant mass effect with signs of obstructive hydrocephalus or tonsillar herniation
- Basilar artery occlusion confirmed as chronic by prior imaging or investigator judgment
- Presence of untreated intracranial aneurysms, tumors (except small meningiomas), or vascular malformations
- Intracranial hemorrhage within the past 6 months
- Active bleeding, coagulation disorders, or uncorrectable bleeding tendencies
- Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases
- Known allergy to iodine contrast agents or treatment-related drugs
- Medically uncontrolled refractory hypertension (systolic >185 mmHg or diastolic >110 mmHg)
- Uncontrollable blood glucose levels (<2.8 mmol/L or >22.2 mmol/L)
- Pregnancy or breastfeeding
- Life expectancy less than 6 months
- Participation in other clinical studies affecting outcome assessment
- Investigator's judgment of unsuitability due to mental illness, cognitive or emotional disorders preventing compliance or understanding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China, 570100
Actively Recruiting
Research Team
Z
Zhengqiang Zhao, PhD
CONTACT
W
Wen Sun, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here